AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15090972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GLP-1 (1.2 pmol x kg x min) for 8 hours
Number of subjects: 8
Study 15090972 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 8 hours
Number of subjects: 8
Study 11296544 — intervention group
Group type: EXPERIMENTAL
Intervention: NIM 200 mg/day
Number of subjects: 80
Study 11296544 — intervention group
Group type: EXPERIMENTAL
Intervention: NIM 400 mg/day
Number of subjects: 80
Study 11296544 — intervention group
Group type: EXPERIMENTAL
Intervention: NIM 100 mg/day
Number of subjects: 80
Study 11296544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9342788 — intervention group
Group type: EXPERIMENTAL
Intervention: THA 25 mg
Number of subjects: 19
Study 9342788 — intervention group
Group type: EXPERIMENTAL
Intervention: THA 50 mg
Number of subjects: 19
Study 8509691 — intervention group
Group type: EXPERIMENTAL
Intervention: Betnesol‐N ear drops
Number of subjects: 162
Study 8509691 — intervention group
Group type: COMPARATOR
Intervention: Control (no ear drops)
Number of subjects: 162
Study 2956876 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (50 to 100 mg 3 times daily)
Number of subjects: 30
Study 29915986 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate loading (CHO)
Number of subjects: 70
Study 29915986 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 27208905 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (600 mg fixed dose)
Number of subjects: 0
Study 27208905 — intervention group
Group type: COMPARATOR
Intervention: Intravenous trastuzumab (8 mg/kg loading, 6 mg/kg maintenance)
Number of subjects: 0
Study 24864325 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser CCI
Number of subjects: 60
Study 24864325 — intervention group
Group type: COMPARATOR
Intervention: Manual CCI
Number of subjects: 60
Study 22413441 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-lateral position (group SL)
Number of subjects: 0
Study 22413441 — intervention group
Group type: COMPARATOR
Intervention: Supine position with uterine displacement (group UD)
Number of subjects: 0
Study 20857869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 58
Study 20857869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 18473286 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine 600 mg per day
Number of subjects: 165
Study 18473286 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine 300 mg per day
Number of subjects: 165
Study 18473286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 15958063 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous haematopoietic stem cell transplant (HSCT)
Number of subjects: 700
Study 12410858 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 10329293 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis (PCA) with varying numbers of principal components retained
Number of subjects: 0
Study 10329293 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic and test set estimates of generalization
Number of subjects: 0
Study 8519722 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (10 micrograms/mL)
Number of subjects: 40
Study 8519722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl/bupivacaine (0.1%) mixture
Number of subjects: 40
Study 8519722 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 1708716 — intervention group
Group type: COMPARATOR
Intervention: No-information condition
Number of subjects: 0
Study 1708716 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial information conditions (direction, hand, extent precued)
Number of subjects: 0
Study 1708716 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial information conditions (all precue conditions)
Number of subjects: 0
Study 1708716 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial information conditions (M3 component)
Number of subjects: 0
Study 7143286 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training for cardiac acceleration (2-5 sessions)
Number of subjects: 24
Study 7143286 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback assisted training in cardiac constancy (1 session)
Number of subjects: 24
Study 7143286 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training for cardiac acceleration
Number of subjects: 24
Study 7143286 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback assisted training in cardiac constancy
Number of subjects: 24
Study 6368958 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2 vitamin D3 (approximately 0.25 microgram/day)
Number of subjects: 28
Study 6368958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30124721 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study 30124721 — intervention group
Group type: COMPARATOR
Intervention: Placebo→Guselkumab
Number of subjects: 0
Study 30124721 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab→Guselkumab
Number of subjects: 0
Study 27128357 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) plus Treatment as Usual (TAU)
Number of subjects: 106
Study 27128357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) plus Treatment as Usual (TAU)
Number of subjects: 106
Study 27128357 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 106
Study 24785463 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboccipital soft tissue inhibition
Number of subjects: 76
Study 24785463 — intervention group
Group type: EXPERIMENTAL
Intervention: Occiput-atlas-axis manipulation
Number of subjects: 76
Study 24785463 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of both techniques
Number of subjects: 76
Study 24785463 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 22582764 — intervention group
Group type: EXPERIMENTAL
Intervention: JASP/ER intervention
Number of subjects: 16
Study 22582764 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 20079617 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 10
Study 20079617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18540738 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Training (ACT)
Number of subjects: 59
Study 18540738 — intervention group
Group type: COMPARATOR
Intervention: Educational Control Workshop
Number of subjects: 59
Study 15863798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (up to 15 mg/day)
Number of subjects: 37
Study 15863798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 15863798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 37
Study 12195728 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg orally for 3 months)
Number of subjects: 7
Study 12195728 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (5 mg intravenously)
Number of subjects: 7
Study 7727324 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose 1 mg morphine epidurally and continuous infusion of bupivacaine 0.75% + 0.2 mg/mL morphine at an infusion rate of 0.8 mL/hr
Number of subjects: 60
Study 7727324 — intervention group
Group type: COMPARATOR
Intervention: Loading dose 0.5 mg morphine epidurally and continuous infusion of bupivacaine 0.75% + 0.1 mg/mL morphine at an infusion rate of 0.8 mL/hr
Number of subjects: 60
Study 2109522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoretic (100 mg atenolol + 25 mg chlorthalidone)
Number of subjects: 24
Study 2109522 — intervention group
Group type: COMPARATOR
Intervention: Atenolol alone (100 mg daily)
Number of subjects: 24
Study 2109522 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone alone (25 mg daily)
Number of subjects: 24
Study 2109522 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg) plus Chlorthalidone (25 mg) taken separately
Number of subjects: 24
Study 6975811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chloramphenicol (75 mg/kg/day)
Number of subjects: 44
Study 6975811 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chloramphenicol
Number of subjects: 44
Study 6975811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chloramphenicol
Number of subjects: 44
Study 30990777 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine-based wound matrix dressing plus negative pressure wound therapy (NPWT)
Number of subjects: 16
Study 30990777 — intervention group
Group type: COMPARATOR
Intervention: Negative pressure wound therapy (NPWT) alone
Number of subjects: 16
Study 30094849 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water (42°C)
Number of subjects: 0
Study 30094849 — intervention group
Group type: COMPARATOR
Intervention: Cold water (23°C)
Number of subjects: 0
Study 30094849 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer cure time
Number of subjects: 0
Study 30094849 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water and longer cure times
Number of subjects: 0
Study 26709567 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-portal technique
Number of subjects: 156
Study 26709567 — intervention group
Group type: COMPARATOR
Intervention: 2-portal technique
Number of subjects: 156
Study 24269494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of social threat
Number of subjects: 0
Study 24269494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of physical pain
Number of subjects: 0
Study 21410537 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-molded rigid heel cup
Number of subjects: 50
Study 21410537 — intervention group
Group type: COMPARATOR
Intervention: Sports shoe without heel cup
Number of subjects: 50
Study 21110140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bassini group
Number of subjects: 552
Study 21110140 — intervention group
Group type: COMPARATOR
Intervention: Tension-free mesh group
Number of subjects: 552
Study 17415690 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% (Trav/Tim)
Number of subjects: 408
Study 17415690 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%/timolol 0.5% (Lat/Tim)
Number of subjects: 408
Study 15704096 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 88
Study 15704096 — intervention group
Group type: COMPARATOR
Intervention: Sham LLLT
Number of subjects: 88
Study 11324406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice
Number of subjects: 58
Study 11324406 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoridated dentifrice
Number of subjects: 58
Study 9390584 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 41
Study 9390584 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 41
Study 8189280 — intervention group
Group type: EXPERIMENTAL
Intervention: Proparacaine (2 drops)
Number of subjects: 47
Study 8189280 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (2 drops)
Number of subjects: 47
Study 3074608 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg/day)
Number of subjects: 14
Study 3074608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30595342 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patient with psychological symptoms
Number of subjects: 225
Study 30595342 — intervention group
Group type: COMPARATOR
Intervention: Male patient with psychological symptoms
Number of subjects: 225
Study 28593473 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab (AMG 334); subcutaneous administration; pharmacokinetics characterized by a two-compartment target-mediated drug disposition model; absorption half-life of 1.6 days; bioavailability of 74%.
Number of subjects: 0
Study 28593473 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab (AMG 334); effects evaluated in relation to body weight, gender, and age.
Number of subjects: 0
Study 25069999 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy with polidocanol 0.5%
Number of subjects: 56
Study 25069999 — intervention group
Group type: COMPARATOR
Intervention: Long‐pulsed neodymium‐doped yttrium aluminium garnet (Nd:YAG) laser
Number of subjects: 56
Study 25069999 — intervention group
Group type: COMPARATOR
Intervention: Both therapies (sclerotherapy and Nd:YAG laser)
Number of subjects: 56
Study 25069999 — intervention group
Group type: COMPARATOR
Intervention: Pain perception
Number of subjects: 56
Study 23591157 — intervention group
Group type: EXPERIMENTAL
Intervention: FBV supplementation for 8 weeks
Number of subjects: 42
Study 23591157 — intervention group
Group type: COMPARATOR
Intervention: Moderate exercise (single bout)
Number of subjects: 42
Study 23591157 — intervention group
Group type: EXPERIMENTAL
Intervention: FBV supplementation and controlled walking
Number of subjects: 42
Study 21891918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo rotary system
Number of subjects: 140
Study 21891918 — intervention group
Group type: COMPARATOR
Intervention: K-file
Number of subjects: 140
Study 19444535 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid (UA) treatment
Number of subjects: 24
Study 19444535 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 24
Study 16772858 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestions for anomalous experiences
Number of subjects: 0
Study 16772858 — intervention group
Group type: COMPARATOR
Intervention: No suggestions for anomalous experiences (Control)
Number of subjects: 0
Study 16772858 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestion condition
Number of subjects: 0
Study 16772858 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual apparitions
Number of subjects: 0
Study 15284771 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (100 mg every 4 hours up to 6 doses)
Number of subjects: 198
Study 15284771 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (administered by standardized protocol)
Number of subjects: 198
Study 15284771 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 198
Study 15284771 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 198
Study 11376176 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical hematoma evacuation within 4 hours of symptom onset
Number of subjects: 11
Study 11376176 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment within 12 hours of symptom onset
Number of subjects: 11
Study 11376176 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller postsurgical hematoma volume
Number of subjects: 11
Study 11376176 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative rebleeding
Number of subjects: 11
Study 9382054 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (mesalamine enema and mesalamine tablets)
Number of subjects: 60
Study 9382054 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine rectal enema
Number of subjects: 60
Study 9382054 — intervention group
Group type: COMPARATOR
Intervention: Oral mesalamine tablets
Number of subjects: 60
Study 8257143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) fluconazole, 100 mg, administered by constant-rate infusion over 30 min
Number of subjects: 10
Study 8257143 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (p.o.) fluconazole, 100 mg
Number of subjects: 10
Study 8257143 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) fluconazole, 100 mg
Number of subjects: 10
Study 4085410 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tiapride
Number of subjects: 20
Study 4085410 — intervention group
Group type: COMPARATOR
Intervention: 1 g aspirin
Number of subjects: 20
Study 30082217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal arginine vasopressin (AVP)
Number of subjects: 653
Study 30243662 — intervention group
Group type: EXPERIMENTAL
Intervention: XP Shaper (XP) operated at 3000 rpm
Number of subjects: 60
Study 30243662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyflex EDM 'one file' (EDM)
Number of subjects: 60
Study 30243662 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne Gold Primary (WOG)
Number of subjects: 60
Study 30243662 — intervention group
Group type: EXPERIMENTAL
Intervention: XP Shaper (XP)
Number of subjects: 60
Study 30243662 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study 26424292 — intervention group
Group type: EXPERIMENTAL
Intervention: Moluodan
Number of subjects: 196
Study 26424292 — intervention group
Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 196
Study 24176199 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Treatment (AT, n=149)
Number of subjects: 279
Study 24176199 — intervention group
Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC, n=130)
Number of subjects: 279
Study 22739219 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 0
Study 22739219 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study 22739219 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 0
Study 20228458 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lycopene 8 mg daily with radiotherapy
Number of subjects: 50
Study 20228458 — intervention group
Group type: COMPARATOR
Intervention: Placebo with radiotherapy
Number of subjects: 50
Study 18572037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (FEN)
Number of subjects: 37
Study 18572037 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG)
Number of subjects: 37
Study 18572037 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restricted diet (CRD)
Number of subjects: 37
Study 15948817 — intervention group
Group type: EXPERIMENTAL
Intervention: NP-LS regimen (prepackaged low-residue diet with LoSo Prep containing magnesium citrate, bisocodyl tablets, and bisocodyl suppository)
Number of subjects: 506
Study 15948817 — intervention group
Group type: COMPARATOR
Intervention: 2F regimen (clear liquid diet with double-dose sodium phosphate)
Number of subjects: 506
Study 12806559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 0
Study 12806559 — intervention group
Group type: COMPARATOR
Intervention: In vitro fertilization (IVF)
Number of subjects: 0
Study 10491521 — intervention group
Group type: EXPERIMENTAL
Intervention: VBMCP + rIFN(alpha2)
Number of subjects: 628
Study 10491521 — intervention group
Group type: COMPARATOR
Intervention: VBMCP
Number of subjects: 628
Study 10491521 — intervention group
Group type: EXPERIMENTAL
Intervention: VBMCP + HiCy
Number of subjects: 628
Study 9177625 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg prolonged-release diclofenac sodium
Number of subjects: 20
Study 9177625 — intervention group
Group type: COMPARATOR
Intervention: 3 enteric-coated tablets/day of 50 mg diclofenac sodium
Number of subjects: 20
Study 8191328 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg prostaglandin E2 (PGE2) gel extra‐amniotically
Number of subjects: 20
Study 8191328 — intervention group
Group type: COMPARATOR
Intervention: 25 mg prostaglandin F2 alpha (PGF2 alpha) intra‐amniotically
Number of subjects: 20
Study 3546147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg t.i.d. orally for ten days
Number of subjects: 32
Study 3546147 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 1 g t.i.d. orally for ten days
Number of subjects: 32
Study 31714396 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal-intensity aerobic interval training (MAIT) at 95-100% of heart rate reserve, 3 d/wk for 4 wk
Number of subjects: 47
Study 31714396 — intervention group
Group type: COMPARATOR
Intervention: High-intensity aerobic interval training (HAIT) at 85% of heart rate reserve, 3 d/wk for 4 wk
Number of subjects: 47
Study 28780493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Assessment in Advanced Dementia (PAINAD) tool
Number of subjects: 602
Study 28780493 — intervention group
Group type: COMPARATOR
Intervention: Standard methods for pain assessment
Number of subjects: 602
Study 26940081 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 100 μg
Number of subjects: 114
Study 26940081 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 5 international units
Number of subjects: 114
Study 23065358 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ stem cell transplantation
Number of subjects: 110
Study 23065358 — intervention group
Group type: COMPARATOR
Intervention: No cell therapy (controls)
Number of subjects: 110
Study 21392602 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs) administered transendocardially
Number of subjects: 60
Study 21392602 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole bone marrow mononuclear cells (BMCs) administered transendocardially
Number of subjects: 60
Study 21392602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both MSC and BMC groups)
Number of subjects: 60
Study 20082783 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic proteins (BMPs)
Number of subjects: 0
Study 17336720 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029
Study 17336720 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 3029
Study 15156256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide treatment for 24 months after 6 months of oral anticoagulants.
Number of subjects: 405
Study 15156256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sulodexide treatment).
Number of subjects: 405
Study 15156256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide treatment for 24 months.
Number of subjects: 405
Study 11384827 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet containing detailed information about potential side effects
Number of subjects: 41
Study 11384827 — intervention group
Group type: COMPARATOR
Intervention: Leaflet without detailed risk information
Number of subjects: 41
Study 9256141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron (2.4 mg/kg I.V. prechemotherapy, followed by 200 mg oral once daily for 6 days)
Number of subjects: 696